#281 ‒ Longevity drugs, aging biomarkers, and updated findings from the Interventions Testing Program (ITP) | Rich Miller, M.D., Ph.D.

Publish Date: 2023/12/4

The Peter Attia Drive

Frequently requested episodes will be transcribed first

Chapters

Shownotes Transcript

No transcript made for this episode yet, you may request it for free.

#281 ‒ Longevity drugs, aging biomarkers, and updated findings from the Interventions Testing Program (ITP) | Rich Miller, M.D., Ph.D.

The Peter Attia Drive

Chapters

What is the Interventions Testing Program (ITP)?

Why are the mice used by the ITP superior for research?

What are the design and outcomes of ITP studies?

What are the challenges of drug formulation for mice?

Which four drugs identified by the ITP extend the lifespan of mice?

What does the success of rapamycin tell us about aging biology?

What other healthspan measures are evaluated by the ITP in stage 2 studies?

How do aging rate indicators differ from biomarkers of aging?

What aging rate indicators are identified through slow-aging mice?

Why are proteomics essential to understand cell changes?

What are the frontiers of unraveling aging rate indicators?

How can we bridge the gap from mice to humans in aging research?

What do laboratory mice die from?

How does a drug improve an age-sensitive outcome versus all aspects of aging?

17⍺-estradiol: mechanisms of life extension and sex differences

Why did resveratrol, metformin, and nicotinamide riboside fail in ITP studies?

What are the over-the-counter successes in the ITP?

Why did fisetin fail to extend lifespan?

Can targeting senescent cells slow aging?

What is the optimism about future findings?

Shownotes Transcript

PodQuest PodQuest Podcast Discovery Engine tailors playlist for your curiosity

#281 ‒ Longevity drugs, aging biomarkers, and updated findings from the Interventions Testing Program (ITP) | Rich Miller, M.D., Ph.D. 02:23:57

The Peter Attia Drive

Chapters

What is the Interventions Testing Program (ITP)?

Why are the mice used by the ITP superior for research?

What are the design and outcomes of ITP studies?

What are the challenges of drug formulation for mice?

Which four drugs identified by the ITP extend the lifespan of mice?

What does the success of rapamycin tell us about aging biology?

What other healthspan measures are evaluated by the ITP in stage 2 studies?

How do aging rate indicators differ from biomarkers of aging?

What aging rate indicators are identified through slow-aging mice?

Why are proteomics essential to understand cell changes?

What are the frontiers of unraveling aging rate indicators?

How can we bridge the gap from mice to humans in aging research?

What do laboratory mice die from?

How does a drug improve an age-sensitive outcome versus all aspects of aging?

17⍺-estradiol: mechanisms of life extension and sex differences

Why did resveratrol, metformin, and nicotinamide riboside fail in ITP studies?

What are the over-the-counter successes in the ITP?

Why did fisetin fail to extend lifespan?

Can targeting senescent cells slow aging?

What is the optimism about future findings?

Shownotes Transcript

PodQuest PodQuest Podcast Discovery Engine tailors playlist for your curiosity

#281 ‒ Longevity drugs, aging biomarkers, and updated findings from the Interventions Testing Program (ITP) | Rich Miller, M.D., Ph.D.